The Impact of Almond Nut Consumption on Markers of CVD & Metabolic Health
Almonds
A Randomised, Controlled Parallel Dietary Intervention to Investigate the Effect of Almond Snack Consumption on Cardio-metabolic Disease Risk Markers Compared With Isocaloric Snacks, in Adults at Moderate Risk of Cardiovascular Disease
1 other identifier
interventional
108
1 country
1
Brief Summary
The purpose of this study is to investigate the cardio-metabolic health effects of consuming almond nuts in place of habitual (usual) snack products in adults at moderate risk of developing cardiovascular disease
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2017
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 30, 2016
CompletedFirst Posted
Study publicly available on registry
September 20, 2016
CompletedStudy Start
First participant enrolled
March 29, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 13, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2019
CompletedDecember 2, 2019
February 1, 2019
2.1 years
August 30, 2016
November 29, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Endothelium-dependent vasodilation
Measured via flow mediated dilation (FMD)
Baseline (week 2)
Endothelium-dependent vasodilation
Measured via flow mediated dilation (FMD)
Week 8 (after 2 week run in)
Liver fat %
Via MRI and magnetic resonance spectroscopy (MRS) analysis. Only a subset of 48 participants with aim of 20 per each arm to complete
Baseline (week 2)
Liver fat %
Via MRI and MRS analysis. Only a subset of 48 participants with aim of 20 per each arm to complete
Week 8 (after 2 week run in)
Secondary Outcomes (63)
Pancreatic fat
Baseline (week 2)
Abdominal fat
Baseline (week 2)
Muscle fat
Baseline (week 2)
Pancreatic fat
Week 8 (after 2 week run in)
Abdominal fat
Week 8 (after 2 week run in)
- +58 more secondary outcomes
Other Outcomes (5)
Adverse events
Through study completion, average of 1.5 years.
Snack product acceptability
Week 6
4 day food diaries
4 days at screening
- +2 more other outcomes
Study Arms (2)
Almonds
EXPERIMENTALAlmond snacks
Control muffins/crackers
PLACEBO COMPARATORMuffin/Cracker snacks
Interventions
Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation.
Eligibility Criteria
You may qualify if:
- Subjects will be male or female, aged between 30-70 years who regularly consume ≥2 snack products a day. A principal aim is to identify and recruit subjects with increased risk of CVD, in order to increase the sensitivity of the study subjects to dietary change. Subjects who are at above average risk for developing CVD (relative risk \>1.5) will be selected using a metabolic scoring system (scoring ≥2 points), adapted from the Framingham risk score system, as used previously by Chong et al. 2012. Subjects will give their own written informed consent.
You may not qualify if:
- Non-snack consumers (assessed as subjects consuming \<2 snack products per day by a specific FFQ (food frequency questionnaire) at screening, adapted from the short Health Survey for England (2007) Eating Habits Questionnaire).
- A reported history of myocardial infarction or cancer.
- Being fitted with a heart pacemaker.
- Presence of metal inside the body (implants, devices, shrapnel, metal particles in eyes from welding etc.). History of black-outs/epilepsy.
- Diabetes mellitus (fasting plasma glucose \>7 mmol/L).
- Chronic coronary, renal or bowel disease or history of cholestatic liver disease or pancreatitis.
- Presence of gastrointestinal disorder or use of a drug, which is likely to alter gastrointestinal motility or nutrient absorption.
- History of substance abuse or alcoholism (past history of alcohol intake \>60 units/men or 50 units/women).
- Currently pregnant, planning pregnancy, breastfeeding or having had a baby in the last 12 months.
- Allergy or intolerance to nuts.
- Unwilling to follow the protocol and/or give informed consent.
- Weight change of \> 3 kg in preceding 2 months. BMI \<18 kg/m2 (underweight) or \>40 kg/m2 (morbidly obese due to potential technical difficulties making FMD and ambulatory blood pressure (ABP) measurements).
- Current smokers or individuals who quit smoking within the last 6 months.
- Participation in other research trials involving dietary or drug intervention and/ or blood collection in the past 3 months.
- Unable or unwilling to comply with study protocol.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- King's College Londonlead
- Almond Board of Californiacollaborator
Study Sites (1)
King's College London, Diabetes and Nutritional Sciences Division
London, SE1 9NH, United Kingdom
Related Publications (1)
Dikariyanto V, Smith L, Francis L, Robertson M, Kusaslan E, O'Callaghan-Latham M, Palanche C, D'Annibale M, Christodoulou D, Basty N, Whitcher B, Shuaib H, Charles-Edwards G, Chowienczyk PJ, Ellis PR, Berry SEE, Hall WL. Snacking on whole almonds for 6 weeks improves endothelial function and lowers LDL cholesterol but does not affect liver fat and other cardiometabolic risk factors in healthy adults: the ATTIS study, a randomized controlled trial. Am J Clin Nutr. 2020 Jun 1;111(6):1178-1189. doi: 10.1093/ajcn/nqaa100.
PMID: 32412597DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sarah Berry, PhD
King's College London
- PRINCIPAL INVESTIGATOR
Wendy Hall, PhD
King's College London
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 30, 2016
First Posted
September 20, 2016
Study Start
March 29, 2017
Primary Completion
May 13, 2019
Study Completion
October 30, 2019
Last Updated
December 2, 2019
Record last verified: 2019-02
Data Sharing
- IPD Sharing
- Will not share